Expert Interview
A third opinion: Discussing the standard of care and potential of AstraZeneca’s Farxiga (dapagliflozin), which recently received FDA approval of label expansion to treat heart failure in a broader range of patients.
Ticker(s): AZNInstitution: HPMG
- treats 50 patients with resistant hypertension
- Board Certified Cardiologist working for the last 13 years as a non-invasive cardiologist
- training focused on non-invasive cardiac imaging, echocardiograms, nuclear tests, Cardiac CT scans and Cardiac MRIs
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
